Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

312 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAFV600E metastatic colorectal cancer.
Elez E, Ros J, Fernández J, Villacampa G, Moreno-Cárdenas AB, Arenillas C, Bernatowicz K, Comas R, Li S, Kodack DP, Fasani R, Garcia A, Gonzalo-Ruiz J, Piris-Gimenez A, Nuciforo P, Kerr G, Intini R, Montagna A, Germani MM, Randon G, Vivancos A, Smits R, Graus D, Perez-Lopez R, Cremolini C, Lonardi S, Pietrantonio F, Dienstmann R, Tabernero J, Toledo RA. Elez E, et al. Among authors: ros j. Nat Med. 2022 Oct;28(10):2162-2170. doi: 10.1038/s41591-022-01976-z. Epub 2022 Sep 12. Nat Med. 2022. PMID: 36097219 Free PMC article.
The safety of ramucirumab for the treatment of colorectal cancer.
Noguerido A, Mulet-Margalef N, Matos I, Ros J, Argilés G, Élez E, Tabernero J. Noguerido A, et al. Among authors: ros j. Expert Opin Drug Saf. 2018 Sep;17(9):945-951. doi: 10.1080/14740338.2018.1506762. Epub 2018 Aug 16. Expert Opin Drug Saf. 2018. PMID: 30073902 Review.
Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria.
Matos I, Martin-Liberal J, García-Ruiz A, Hierro C, Ochoa de Olza M, Viaplana C, Azaro A, Vieito M, Braña I, Mur G, Ros J, Mateos J, Villacampa G, Berché R, Oliveira M, Alsina M, Elez E, Oaknin A, Muñoz-Couselo E, Carles J, Felip E, Rodón J, Tabernero J, Dienstmann R, Perez-Lopez R, Garralda E. Matos I, et al. Among authors: ros j. Clin Cancer Res. 2020 Apr 15;26(8):1846-1855. doi: 10.1158/1078-0432.CCR-19-2226. Epub 2019 Nov 22. Clin Cancer Res. 2020. PMID: 31757877
Combined Analysis of Concordance between Liquid and Tumor Tissue Biopsies for RAS Mutations in Colorectal Cancer with a Single Metastasis Site: The METABEAM Study.
Kagawa Y, Elez E, García-Foncillas J, Bando H, Taniguchi H, Vivancos A, Akagi K, García A, Denda T, Ros J, Nishina T, Baraibar I, Komatsu Y, Ciardiello D, Oki E, Kudo T, Kato T, Yamanaka T, Tabernero J, Yoshino T. Kagawa Y, et al. Among authors: ros j. Clin Cancer Res. 2021 May 1;27(9):2515-2522. doi: 10.1158/1078-0432.CCR-20-3677. Epub 2021 Feb 18. Clin Cancer Res. 2021. PMID: 33602686
Biomarker-Guided Anti-Egfr Rechallenge Therapy in Metastatic Colorectal Cancer.
Ciardiello D, Martini G, Famiglietti V, Napolitano S, De Falco V, Troiani T, Latiano TP, Ros J, Elez Fernandez E, Vitiello PP, Maiello E, Ciardiello F, Martinelli E. Ciardiello D, et al. Among authors: ros j. Cancers (Basel). 2021 Apr 17;13(8):1941. doi: 10.3390/cancers13081941. Cancers (Basel). 2021. PMID: 33920531 Free PMC article. Review.
Up-to-date role of aflibercept in the treatment of colorectal cancer.
Saoudi Gonzalez N, Salvà F, Ros J, Baraibar I, Marmolejo D, Valdivia A, Cuadra-Urteaga JL, Mulet N, Tabernero J, Élez E. Saoudi Gonzalez N, et al. Among authors: ros j. Expert Opin Biol Ther. 2021 Oct;21(10):1315-1324. doi: 10.1080/14712598.2021.1935231. Epub 2021 Jun 13. Expert Opin Biol Ther. 2021. PMID: 34085884 Review.
312 results